Acropolis Investment Management LLC Has $1.92 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

Acropolis Investment Management LLC increased its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 39.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,009 shares of the biopharmaceutical company's stock after buying an additional 9,564 shares during the quarter. Acropolis Investment Management LLC's holdings in Bristol-Myers Squibb were worth $1,924,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BMY. Thurston Springer Miller Herd & Titak Inc. grew its holdings in Bristol-Myers Squibb by 28.3% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 5,816 shares of the biopharmaceutical company's stock worth $329,000 after buying an additional 1,284 shares in the last quarter. Park Avenue Securities LLC boosted its position in Bristol-Myers Squibb by 32.6% during the 4th quarter. Park Avenue Securities LLC now owns 56,806 shares of the biopharmaceutical company's stock worth $3,213,000 after acquiring an additional 13,952 shares during the period. Kathmere Capital Management LLC grew its stake in shares of Bristol-Myers Squibb by 33.3% in the fourth quarter. Kathmere Capital Management LLC now owns 10,638 shares of the biopharmaceutical company's stock worth $602,000 after purchasing an additional 2,656 shares in the last quarter. SS&H Financial Advisors Inc. raised its stake in shares of Bristol-Myers Squibb by 10.3% during the fourth quarter. SS&H Financial Advisors Inc. now owns 53,900 shares of the biopharmaceutical company's stock valued at $3,049,000 after purchasing an additional 5,025 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC lifted its holdings in Bristol-Myers Squibb by 6.4% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 15,928 shares of the biopharmaceutical company's stock worth $901,000 after purchasing an additional 960 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on BMY shares. Daiwa America upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 13th. Leerink Partners raised Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $55.00 to $73.00 in a report on Tuesday, November 12th. Cantor Fitzgerald reiterated a "neutral" rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. BMO Capital Markets upped their price objective on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a "market perform" rating in a report on Tuesday, November 12th. Finally, Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a research report on Wednesday, November 13th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $56.27.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. The trade was a 5.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Samit Hirawat acquired 1,830 shares of the company's stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares of the company's stock, valued at $3,395,499.03. The trade was a 3.04 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Up 0.4 %

NYSE BMY traded up $0.22 on Wednesday, hitting $55.96. 8,456,999 shares of the stock were exchanged, compared to its average volume of 9,285,047. The company's 50-day moving average price is $57.44 and its two-hundred day moving average price is $51.76. The company has a market capitalization of $113.50 billion, a price-to-earnings ratio of -15.59, a P/E/G ratio of 15.20 and a beta of 0.45. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same period in the previous year, the firm earned $2.00 earnings per share. Bristol-Myers Squibb's quarterly revenue was up 8.4% on a year-over-year basis. Research analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.43%. The ex-dividend date of this dividend is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's dividend payout ratio is currently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.